Is lung cancer in women different?;Le cancer du poumon chez la femme est-il différent?

Revue Medicale Suisse

Volumn 8, Issue 342, 2012, Pages 1108-1111

  Ben Aissa, A ^a   Mach, N ^a  

^a Division d'Oncologie   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

FEMALE; HISTOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOLECULAR BIOLOGY; MUTATION; REVIEW; SEX DIFFERENCE;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; PROGNOSIS; SEX CHARACTERISTICS; TREATMENT OUTCOME;

EID: 84863887912     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
2. Gorlova OY, Zhang Y, Schabath MB, et al. Never smokers and lung cancer risk: A case-control study of epidemiological factors. Int J Cancer 2006;118:1798-804. (Pubitemid 43376446)
3. Freedman ND, Leitzmann MF, Hollenbeck AR, et al. Cigarette smoking and subsequent risk of lung cancer in men and women: Analysis of a prospective cohort study. Lancet Oncol 2008;9:649-56.
4. Visbal AL, Williams BA, Nichols FC, et al. Gender differences in non-small cell lung cancer survival: An analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg 2004;78:209-15; discussion 215.
5. Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: Age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol 2002;13:1087-93.
6. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33. (Pubitemid 34761611)
7. Chlebowski RT, Schwartz AG, Wakelee H, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): A post-hoc analysis of a randomised controlled trial. Lancet 2009;374:1243-51.
8. Slatore CG, Chien JW, Au DH, et al. Lung cancer and hormone replacement therapy: Association in the vitamins and lifestyle study. J Clin Oncol 2010;28:1540-6.
9. Bouchardy C, Benhamou S, Schaffar R, et al. Lung cancer mortality risk among breast cancer patients treated with anti-estrogens. Cancer 2011;117:1288-95.
10. Stabile LP, Davis AL, Gubish CT, et al. Human nonsmall cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 2002;62:2141-50. (Pubitemid 34408463)
11. Wei Q, Cheng L, Amos CI, et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: A molecular epidemiologic study. J Natl Cancer Inst 2000; 92:1764-72.
12. Dresler CM, Fratelli C, Babb J, et al. Gender differences in genetic susceptibility for lung cancer. Lung Cancer 2000;30:153-60. (Pubitemid 32007871)
13. Donington JS, Colson YL. Sex and gender differences in non-small cell lung cancer. Semin Thorac Cardiovasc Surg 2011;23:137-45.
14. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44.
15. Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004;10:8195-203.
16. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
17. Wisnivesky JP, Halm EA. Sex differences in lung cancer survival: Do tumors behave differently in elderly women? J Clin Oncol 2007;25:1705-12. (Pubitemid 46797951)
18. de Perrot M, Licker M, Bouchardy C, et al. Sex differences in presentation, management, and prognosis of patients with non-small cell lung carcinoma. J Thorac Cardiovasc Surg 2000;119:21-6. (Pubitemid 30046309)
19. Cerfolio RJ, Bryant AS, Scott E, et al. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest 2006;130:1796-802. (Pubitemid 46033436)
20. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9.
21. Werner-Wasik M, Scott C, Cox JD, et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with Locally-Advanced Non-Small Cell Lung Cancer (LA-NSCLC): Identification of five groups with different survival. Int J Radiat Oncol Biol Phys 2000;48:1475-82.
22. Wakelee HA, Dahlberg SE, Brahmer JR, et al. Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab. Lung Cancer 2012; epub ahead of print.
23. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 2009;373:1525-31.
24. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 2006;355:2542-50. (Pubitemid 44917502)
25. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
26. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutationpositive non-small cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.